» Articles » PMID: 37464111

The Combination of Non-contrast Abbreviated MRI and Alpha Foetoprotein Has High Performance for Hepatocellular Carcinoma Screening

Abstract

Objectives: This study aimed to compare two abbreviated MRI (AMRI) protocols to complete MRI for HCC detection: non-contrast (NC)-AMRI without/with alpha foetoprotein (AFP) and dynamic contrast-enhanced (Dyn)-AMRI.

Methods: This retrospective single-center study included 351 patients (M/F: 264/87, mean age: 57y) with chronic liver disease, who underwent MRI for HCC surveillance between 2014 and 2020. Two reconstructed AMRI sets were obtained based on complete MRI: NC-AMRI (T2-weighted imaging (WI) + diffusion-WI) and Dyn-AMRI (T2-WI + dynamic T1-WI) and were assessed by 2 radiologists who reported all suspicious lesions, using LI-RADS/adapted LI-RADS classification. The reference standard was based on all available patient data. Inter-reader agreement was assessed and MRI diagnostic performance was compared to the reference standard.

Results: The reference standard demonstrated 83/351 HCC-positive patients (prevalence: 23.6%, median size: 22 mm, and positive MRIs: 83/631). Inter-reader agreement was substantial for all sets. Sensitivities of Dyn-AMRI and complete MRI (both 92.8%) were similar, higher than NC-AMRI (72.3%, p < 0.001). Specificities were not different between sets. NC-AMRI + AFP (92.8%) had similar sensitivity to Dyn-AMRI and complete MRI. In patients with small size HCCs (≤ 2 cm), sensitivities of Dyn-AMRI (85.3%) and complete MRI (88.2%) remained similar (p = 0.564), also outperforming NC-AMRI (52.9%, p < 0.05). NC-AMRI + AFP had similar sensitivity (88.2%) to Dyn-AMRI and complete MRI (p = 0.706 and p = 1, respectively).

Conclusions: Dyn-AMRI has similar diagnostic performance to complete MRI for HCC detection, while both outperform NC-AMRI, especially for small size HCCs. NC-AMRI + AFP demonstrates similar sensitivity to Dyn-AMRI and complete MRI.

Clinical Relevance Statement: Due to the low sensitivity of ultrasound for hepatocellular screening, new screening methods are needed. Abbreviated MRI (AMRI) is a candidate, especially non-contrast AMRI with serum alpha foetoprotein as the acquisition time is low, without the need for contrast medium injection.

Key Points: • Dynamic contrast-enhanced abbreviated MRI using extracellular gadolinium-based contrast agent and complete MRI have similar diagnostic performance for hepatocellular carcinoma detection in an at-risk population. • Non-contrast abbreviated MRI with alpha foetoprotein has similar diagnostic performance to dynamic contrast-enhanced abbreviated MRI and complete MRI, including when considering small size hepatocellular carcinoma  ≤ 2 cm. • Non-contrast abbreviated MRI and dynamic contrast-enhanced abbreviated MRI can be performed in 7 and 10 min, excluding patient setup time.

Citing Articles

Hepatocellular Carcinoma: Imaging Advances in 2024 with a Focus on Magnetic Resonance Imaging.

Renzulli M, Giampalma E Curr Oncol. 2025; 32(1).

PMID: 39851956 PMC: 11764374. DOI: 10.3390/curroncol32010040.


Magnetic Resonance Imaging Liver Segmentation Protocol Enables More Consistent and Robust Annotations, Paving the Way for Advanced Computer-Assisted Analysis.

Jeltsch P, Monnin K, Jreige M, Fernandes-Mendes L, Girardet R, Dromain C Diagnostics (Basel). 2025; 14(24.

PMID: 39767146 PMC: 11726866. DOI: 10.3390/diagnostics14242785.


Abbreviated magnetic resonance imaging in hepatocellular carcinoma surveillance: A review.

Ramegowda R, Gupta P Indian J Gastroenterol. 2024; 43(6):1090-1098.

PMID: 38460056 DOI: 10.1007/s12664-023-01511-z.


Diagnostic Performance of Abbreviated MRI for HCC Detection in Patients with Non-alcoholic Fatty Liver Disease.

Soundararajan R, Pooja A, Gupta P, Gulati A, Kalra N, Singh S J Clin Exp Hepatol. 2023; 14(1):101276.

PMID: 38076364 PMC: 10709163. DOI: 10.1016/j.jceh.2023.08.012.


HCC screening with non-contrast MRI and alpha-fetoprotein: combining a new player with an old friend.

Amorim J Eur Radiol. 2023; 33(10):6927-6928.

PMID: 37548693 DOI: 10.1007/s00330-023-09934-0.

References
1.
Ryerson A, Eheman C, Altekruse S, Ward J, Jemal A, Sherman R . Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer. 2016; 122(9):1312-37. PMC: 4840031. DOI: 10.1002/cncr.29936. View

2.
Heimbach J, Kulik L, Finn R, Sirlin C, Abecassis M, Roberts L . AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2017; 67(1):358-380. DOI: 10.1002/hep.29086. View

3.
Omata M, Cheng A, Kokudo N, Kudo M, Lee J, Jia J . Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017; 11(4):317-370. PMC: 5491694. DOI: 10.1007/s12072-017-9799-9. View

4.
Kim S, An J, Lim Y, Han S, Lee J, Byun J . MRI With Liver-Specific Contrast for Surveillance of Patients With Cirrhosis at High Risk of Hepatocellular Carcinoma. JAMA Oncol. 2016; 3(4):456-463. PMC: 5470420. DOI: 10.1001/jamaoncol.2016.3147. View

5.
Singal A, Volk M, Waljee A, Salgia R, Higgins P, Rogers M . Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009; 30(1):37-47. PMC: 6871653. DOI: 10.1111/j.1365-2036.2009.04014.x. View